Current and future treatments for Alzheimer's disease

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 1, 2013, Pages 19-33

  Yiannopoulou, Konstantina G ^a   Papageorgiou, Sokratis G ^b  

^a Laiko General Hospital of Athens   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Alzheimer's disease; amyloid; disease modifying drugs; inflammation; tau protein; therapeutic targets

Indexed keywords

ACETYLCHOLINE; AMFEBUTAMONE; AMYLOID BETA PROTEIN; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; DULOXETINE; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; MEMANTINE; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

ABDOMINAL CRAMP; AGITATION; ALZHEIMER DISEASE; ANXIETY DISORDER; BRADYCARDIA; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CHOLESTEROL METABOLISM; CHOLINERGIC TRANSMISSION; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FAINTNESS; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP FRACTURE; HUMAN; IMMUNOTHERAPY; INFLAMMATION; IRON METABOLISM; LIVER TOXICITY; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; NAUSEA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN AGGREGATION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SENILE PLAQUE; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84871643821     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612461679     Document Type: Review

References (81)

1. Adlard P. Bush A. (2006) Metals and Alzheimer's disease. J Alzheimers Dis 10: 145–163.
2. Aisen P. Saumier D. Briand R. Laurin J. Gervais F. Tremblay P. et al. (2006) A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67: 1757–1763.
3. Aisen P. Schafer K. Grundman M. Pfeiffer E. Sano M. Davis K. et al. (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA 289: 2819–2826.
4. Aisen P. Schmeidler J. Pasinetti G. (2002) Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 58: 1050–1054.
5. Albert J.S. (2009) Progress in the development of beta-secretase inhibitors for Alzheimer's disease. Prog Med Chem 48: 133–361.
6. Alfirevic A. Mills T. Carr D. Barratt B. Jawaid A. Sherwood J. et al. (2007) Tacrine-induced liver damage: an analysis of 19 candidate genes. Pharmacogenet Genomics 17: 1091–1100.
7. Almkvist O. Darreh-Shori T. Stefanova E. Spiegel R. Nordberg A. (2004) Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Eur J Neurol 11: 253–261.
8. Alva G. Cummings J. (2008) Relative tolerability of Alzheimer's disease treatments. Psychiatry (Edgmont) 5: 27–36.
9. Ballard C. Corbett A. (2010) Management of neuropsychiatric symptoms in people with dementia. CNS Drugs 24: 729–739.
10. Ballard C. Corbett A. Chitramohan R. Aarsland D. (2009) Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Curr Opin Psychiatry 22: 532–540.
11. Banerjee S. Hellier J. Dewey M. Romeo R. Ballard C. Baldwin R. (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378: 403–411.
12. Barten D. Albright C. (2008) Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 37: 171–186.
13. Bartus R. Dean R. Beer B. Lippa A. (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408–414.
14. Bilikiewicz A. Gaus W. (2004). Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimers Dis 6: 17–26.
15. Birks J. (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (1): CD005593.
16. Blesa R. Ballard C. Orgogozo R. Lane J. Thomas S. (2007) Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 69: 23–28.
17. Brody D. Holtzman D. (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31: 175–193.
18. Cummings J. (2008 a) Optimizing phase II of drug development for disease-modifying compounds. Alzheimers Dement 4(1 Suppl. 1): 15–20.
19. Cummings J. (2008 b) The black book of Alzheimer's disease, part 1. Primary Psychiatry 15: 66–76.
20. Cummings J. Back C. (1998) The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 6: 64–78.
21. Cummings J. Jones R. Wilkinson D. Lopez O. Gauthier S. Waldemar G. et al. (2010) Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. J Alzheimers Dis 21: 843–851.
22. Dodel R. Neff F. Noelker C. Pul R. Du Y. Bacher M. et al. (2010) Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 70: 513–528.
23. Dubois B. Feldman H.H. Jacova C. Cummings J.L. Dekosky S.T. Barberger-Gateau P. et al. (2010) Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9:1118–1127.
24. Farlow M. (2002) A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr 14(Suppl. 1): 93–126.
25. Farlow M. Alva G. Meng X. Olin J. (2010) A 25-week, open label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin 26: 263–269.
26. Farlow M. Anand R. Messina J. Hartman R. Jr Veach J. (2000) A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 44: 236–241.
27. Faux N. Ritchie C. Gunn A. Rembach A. Tsatsanis A. Bedo J. et al. (2010) PBT 2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J Alzheimers Dis 20: 509–516.
28. Feldman H. Doody R. Kivipelto M. Sparks D. Waters D. Jones R. et al. (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74: 956–964.
29. Feldman H. Schmitt F. Olin J. Memantine MEM-MD-02 Study Group (2006) ADL in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 20: 263–268.
30. Ferri C. Prince M. Brayne C. Brodaty H. Fratiglioni L. Ganguli M. et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112–2117.
31. Forlenza O. Diniz B. Radanovic M. Santos F. Talib L. Gattaz W. (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198: 351–356.
32. Galimberti D. Scarpini E. (2011) Disease-modifying treatments for Alzheimer's disease. Ther Adv Neurol Disord 4: 203–216.
33. Gauthier S. Aisen P. Ferris S. Saumier D. Duong A. Haine D. et al. (2009) Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging 13: 550–557.
34. Ghosh A. Brindisi M. Tang J. (2012) Developing β-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem 120: 71–83.
35. Gill S. Anderson G. Fischer H. Bell C. Li P. Normand S. et al. (2009) Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 169: 867–873.
36. Gilman S. Koller M. Black R. Jenkins L. Griffith S. Fox N. et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553–1562.
37. Golde T. (2005) The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol 15: 84–87.
38. Griffin W. (2006) Inflammation and neurodegenerative diseases. Am J Clin Nutr 3(Suppl.): 470–474.
39. Griffin W. (2008) Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation 5: 3.
40. Gura T. (2008) Hope in Alzheimer's fight emerges from unexpected places. Nat Med 14: 894.
41. Hampel H. Ewers M. Bürger K. Annas P. Mörtberg A. Bogstedt A. et al. (2009) Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70: 922–931.
42. Hansen R. Gartlehner G. Webb A. Morgan L. Moore C. Jonas D. (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 3: 211–225.
43. Hara H. Mouri A. Yonemitsu Y. Nabeshima T. Tabira T. (2011) Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1-43/IL-10 cDNA. Vaccine 29: 7474–7482.
44. Herrmann N. Chau S. Kircanski I. Lanctôt K. (2011) Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs 71: 2031–2065.
45. Hey J. Koelsch G. Bilcer G. Jacobs A. Tolar M. Tang J. et al (2008) Single dose administration of the b-secretase inhibitor CTS 21166 (ASP1720) reduces plasma Aβ40 in human subjects. Presented by Dr Koelsch in the International Conference on Alzheimer's Disease (ICAD), Chicago, IL, USA, 26–31 July 2008. Available at: http://www.alzforum.org/new/detail.asp?id=1790
46. Hock C. Nitsch R. (2005) Clinical observations with AN 1792 using TAPIR analyses. Neurodegener Dis 2: 273–276.
47. Hooijmans C. Kiliaan A. (2008) Fatty acids, lipid metabolism and Alzheimer pathology. Eur J Pharmacol 585: 176–196.
48. Howard R. McShane R. Lindesay J. Ritchie C. Baldwin A. Barber R. et al. (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366: 893–903.
49. Imbimbo B. Giardina G. (2011) γ-Secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem 11: 1555–1570.
50. Jick H. Zornberg G. Jick S. Seshadri S. Drachman D. (2000) Statins and the risk of dementia. Lancet 356: 1627–1631.
51. John S. Thangapandian S. Sakkiah S. Lee K. (2011) Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies. BMC Bioinformatics 12(Suppl. 1): 28.
52. Maidment I. Fox C. Boustani M. Rodriguez J. Brown R. Katona C. (2008) Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 42: 32–38.
53. Mancuso C. Siciliano R. Barone E. Butterfield D. Preziosi P. (2011) Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opin Investig Drugs 20: 1243–1261.
54. Martinez A. Perez D. (2008) GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 15: 181–191.
55. McGuinness B. O'Hare J. Craig D. Bullock R. Malouf R. Passmore P. (2010) Statins for the treatment of dementia. Cochrane Database Syst Rev (8): CD007514.
56. McShane R. Areosa Sastre A. Minakaran N. (2006) Memantine for dementia. Cochrane Database Syst Rev (2): CD003154.
57. Panza F. Solfrizzi V. Frisardi V. Capurso C. D'Introno A. Colacicco A.M. et al. (2009) Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 26: 537–555.
58. Qaseem A. Snow V. Cross J. Forciea M. Jr Hopkins R. Shekelle P. Jr et al. American College of Physicians / American Academy of Family Physicians Panel on Dementia (2008) Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 148: 370–378.
59. Qu B. Lambracht-Washington D. Fu M. Eagar T. Stüve O. Rosenberg R. (2010) Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine 28: 5280–5287.
60. Rakover I. Arbel M. Solomon B. (2007) Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg 2576 mice without a significant effect on brain abeta levels. Neurodegener Dis 4: 392–402.
61. Reddy V. Zhu X. Perry G. Smith M. (2009) Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 16: 763–774.
62. Rogers J. Kirby L.C. Hempelman S.R. Berry D.L. McGeer P.L. Kaszniak A.W. et al. (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609–1611.
63. Salloway S. Sperling R. Keren R. Porsteinsson A. van Dyck C. Tariot P. et al. ELND005-AD201 Investigators (2011) A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77: 1253–1262.
64. Salomone S. Caraci F. Leggio G. Fedotova J. Drago F. (2011) New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 73: 504–517.
65. Sano M. Bell K. Galasko D. Galvin J. Thomas R. van Dyck C. et al. (2011) A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77: 556–563.
66. Santa-Maria I. Hernández F. Del Rio J. Moreno F. Avila J. (2007) Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol Neurodegener 2: 17.
67. Siemers E. Skinner M. Dean R. Gonzales C. Satterwhite J. Farlow M. et al. (2005) Safety, tolerability, and changes in amyloid β concentrations after administration of a γ-secretase inhibitor in volunteers. Clin Neuropharmacol 28: 126–132.
68. Silvestri R. (2009) Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. Med Res Rev 29: 295–338.
69. Sperling R. Aisen P. Beckett L. Bennett D. Craft S. Fagan A. et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280–292.
70. Stefani M. Liguri G. (2009) Cholesterol in Alzheimer's disease: unresolved questions. Curr Alzheimer Res 6: 15–29.
71. Tariot P. Farlow M. Grossberg G. Graham S. McDonald S. Gergel I. (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291: 317–324.
72. Tong G. Wang J. Sverdlov O. Huang S. Slemmon R. Croop R. et al. (2012) Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163: tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin Ther 34: 654–667.
73. Vassar R. (2004) BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 23: 105–114.
74. Vellas B. Aisen P. Sampaio C. Carrillo M. Scheltens P. Scherrer B. et al. (2011) Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol 95: 594–600.
75. Vellas B. Andrieu S. Sampaio C. Wilcock G. (2007) Disease-modifying trials in Alzheimer's disease: a European Task Force consensus. Lancet Neurol 6: 56–62.
76. Vellas B. Sol O. Snyder P. Ousset P. Haddad R. Maurin M. et al. EHT0202/002 study group (2011) EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 8: 203–212.
77. Wilcock D. Jantzen P. Li Q. Morgan D. Gordon M. (2007) Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144: 950–960.
78. Wisniewski T. Konietzko U. (2008) Amyloid-β immunization for Alzheimer's disease. Lancet Neurol 7: 805–811.
79. Wong G. Manfra D. Poulet F. Zhang Q. Josien H. Bara T. et al. (2004) Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibit β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279: 12876–12882.
80. Yiannopoulou K. Karydakis K. Sakka P. (2009) Therapeutic targets in Alzheimer's disease. Primary Psychiatry 16: 29–36.
81. Zec R. Burkett N. (2008) Non-pharmacological and pharmacological treatment of the cognitive and behavioral symptoms of Alzheimer disease. NeuroRehabilitation 23: 425–438.